AU2019274652B2 - Monospecific and multispecific anti-TMEFF2 antibodies and there uses - Google Patents

Monospecific and multispecific anti-TMEFF2 antibodies and there uses

Info

Publication number
AU2019274652B2
AU2019274652B2 AU2019274652A AU2019274652A AU2019274652B2 AU 2019274652 B2 AU2019274652 B2 AU 2019274652B2 AU 2019274652 A AU2019274652 A AU 2019274652A AU 2019274652 A AU2019274652 A AU 2019274652A AU 2019274652 B2 AU2019274652 B2 AU 2019274652B2
Authority
AU
Australia
Prior art keywords
seq
tmeff2
antibody
binding fragment
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019274652A
Other languages
English (en)
Other versions
AU2019274652A1 (en
Inventor
Phillip Cooper
Robin Ernst
Rajkumar Ganesan
Colleen Kane
Michael Russell
Sanjaya Singh
Sathyadevi VENKATARAMANI
Sheng-Jiun Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AU2019274652A1 publication Critical patent/AU2019274652A1/en
Application granted granted Critical
Publication of AU2019274652B2 publication Critical patent/AU2019274652B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019274652A 2018-05-24 2019-05-21 Monospecific and multispecific anti-TMEFF2 antibodies and there uses Active AU2019274652B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675957P 2018-05-24 2018-05-24
US62/675,957 2018-05-24
PCT/IB2019/054184 WO2019224713A2 (en) 2018-05-24 2019-05-21 Monospecific and multispecific anti-tmeff2 antibodies and there uses

Publications (2)

Publication Number Publication Date
AU2019274652A1 AU2019274652A1 (en) 2020-11-26
AU2019274652B2 true AU2019274652B2 (en) 2026-03-26

Family

ID=67211771

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019274652A Active AU2019274652B2 (en) 2018-05-24 2019-05-21 Monospecific and multispecific anti-TMEFF2 antibodies and there uses

Country Status (25)

Country Link
US (1) US11866499B2 (enExample)
EP (1) EP3802607A2 (enExample)
JP (2) JP2021524255A (enExample)
KR (1) KR20210011999A (enExample)
CN (1) CN112703203B (enExample)
AR (1) AR115419A1 (enExample)
AU (1) AU2019274652B2 (enExample)
BR (1) BR112020023416A2 (enExample)
CA (1) CA3101304A1 (enExample)
CL (1) CL2020003032A1 (enExample)
CO (1) CO2020014515A2 (enExample)
CR (1) CR20200564A (enExample)
EA (1) EA202092849A1 (enExample)
EC (1) ECSP20075234A (enExample)
IL (1) IL278862A (enExample)
JO (1) JOP20200295A1 (enExample)
MA (1) MA52772A (enExample)
MX (1) MX2020012589A (enExample)
NI (1) NI202000087A (enExample)
PE (1) PE20210634A1 (enExample)
PH (1) PH12020551948A1 (enExample)
SG (1) SG11202011268VA (enExample)
TW (1) TWI865451B (enExample)
UY (1) UY38243A (enExample)
WO (1) WO2019224713A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
PH12022551470A1 (en) * 2019-12-18 2023-05-03 Janssen Biotech Inc Materials and methods for in vivo biological targeting
PE20230389A1 (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
US20230374140A1 (en) * 2020-10-09 2023-11-23 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
EP4583980A1 (en) * 2022-09-09 2025-07-16 Janssen Biotech, Inc. Method of treating cancer with an anti tmeff2xcd3 bispecific antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093122A2 (en) * 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US226A (en) 1837-06-03 Samuel goss
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
WO2003075855A2 (en) 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
BRPI0818780A2 (pt) * 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
PT2970980T (pt) 2013-03-15 2018-11-19 Janssen Biotech Inc Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
DK3189081T3 (da) 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
EP3778640A1 (en) * 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP3310811B1 (en) * 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
BR112020023508A2 (pt) 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093122A2 (en) * 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AFAR DANIEL E H ET AL: "Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 3, no. 8, 1 August 2004 (2004-08-01), US, pages 921 - 932, XP002396164, ISSN: 1535-7163 *

Also Published As

Publication number Publication date
IL278862A (en) 2021-01-31
SG11202011268VA (en) 2020-12-30
UY38243A (es) 2019-11-29
AU2019274652A1 (en) 2020-11-26
NI202000087A (es) 2021-03-23
TWI865451B (zh) 2024-12-11
JP2021524255A (ja) 2021-09-13
MX2020012589A (es) 2021-01-29
CR20200564A (es) 2021-06-21
PE20210634A1 (es) 2021-03-23
JOP20200295A1 (ar) 2020-11-22
US11866499B2 (en) 2024-01-09
JP2024105476A (ja) 2024-08-06
US20190359711A1 (en) 2019-11-28
CO2020014515A2 (es) 2020-12-10
WO2019224713A2 (en) 2019-11-28
PH12020551948A1 (en) 2021-08-16
CN112703203B (zh) 2025-02-25
ECSP20075234A (es) 2020-12-31
CL2020003032A1 (es) 2021-04-16
CA3101304A1 (en) 2019-11-28
EA202092849A1 (ru) 2021-03-16
TW202003584A (zh) 2020-01-16
EP3802607A2 (en) 2021-04-14
KR20210011999A (ko) 2021-02-02
CN112703203A (zh) 2021-04-23
BR112020023416A2 (pt) 2021-02-17
MA52772A (fr) 2021-04-14
WO2019224713A3 (en) 2020-01-02
AR115419A1 (es) 2021-01-13

Similar Documents

Publication Publication Date Title
US20230322924A1 (en) Anti-cd3 antibodies and uses thereof
JP7506817B2 (ja) カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用
US11866499B2 (en) Monospecific and multispecific anti-TMEFF2 antibodies and their uses
US11746157B2 (en) PSMA binding agents and uses thereof
AU2019326635B2 (en) Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
TW201809005A (zh) 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
EP4284838A2 (en) Psma binding proteins and uses thereof
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
CN119161478A (zh) α5β1整合素结合剂及其用途
JP7625516B2 (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
US10584175B2 (en) FN14-binding proteins and uses thereof
HK40126767A (en) Anti-cd3 antibodies and uses thereof
EA045935B1 (ru) Антитела к cd3 и их применение
HK40052977A (en) Anti-cd3 antibodies and uses thereof
BR112021003089B1 (pt) Anticorpos biespecíficos anti-pd-l1/anti-lag3 e composição farmacêutica

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)